Biological Products, Except Diagnostic Substances (Biotech) - Insider Trading Data

Insiders are officers, directors, or significant investors. This page shows insider sentiment and transactions for the Biological industry. Research shows that insider trades are predictive of future stock returns. By examining insider trades for an industry, we can understand what well-informed people think of the overall future industry prospects.

Biological Products, Except Diagnostic Substances (Biotech) - Insider Buy/Sell Ratio

Insider selling and buying is a useful indicator for analyzing the market because it serves as a proxy for their optimism or pessimism in their own companies. By looking at ratio of total selling and buying across the entire market, we might be able to draw some conclusions about the future market.

We offer two charts here. The first one shows the total dollar volume of buying and selling by insiders. The second chart shows the ratio of the number of insiders selling, vs. the number of insiders buying. In both charts, we filter out trades made by indirect holders (such as trusts), and 10% owners (who, although considered an 'insider' by the SEC, do not actually manage the companies in which they are considered insiders).

Corporate Insider Buy Sell Ratio (Dollar Volume) - Biological Products, Except Diagnostic Substances (Biotech)
Corporate Insider Buy Sell Ratio (Insider Count) - Biological Products, Except Diagnostic Substances (Biotech)
Biological Products, Except Diagnostic Substances (Biotech) - Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b5-1 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Security Form Insider Code 10b5-1 Direct Share
Price
Shares
Changed
2025-09-10 RGEN / Repligen Corporation 4 Hunt Anthony S - Sale D 116.34 -96
2025-09-10 RGEN / Repligen Corporation 4 Hunt Anthony S - Sale D 122.23 -2,179
2025-09-10 RGEN / Repligen Corporation 4 Hunt Anthony S - Sale D 119.64 -3,262
2025-09-10 RGEN / Repligen Corporation 4 Hunt Anthony S - Sale D 121.42 -7,584
2025-09-10 HALO / Halozyme Therapeutics, Inc. 4 LaBrosse Nicole S - Sale D 75.929 -13,240
2025-09-10 RGEN / Repligen Corporation 4 Hunt Anthony S - Sale D 118.32 -1,108
2025-09-10 HALO / Halozyme Therapeutics, Inc. 4 LaBrosse Nicole S - Sale D 75.291 -6,760
2025-09-10 RGEN / Repligen Corporation 4 Hunt Anthony S - Sale D 120.19 -14,882
2025-09-10 VOR / Vor Biopharma Inc. 4 Reprogrammed Interchange LLC S - Sale D 1.8151 -350,000
2025-09-10 ELUT / Elutia Inc. 4 Mills C Randal M - Exercise D 27,083
2025-09-10 HALO / Halozyme Therapeutics, Inc. 4 LaBrosse Nicole M - Exercise D 12.49 1,135
2025-09-10 GILD / Gilead Sciences, Inc. 4 Mercier Johanna M - Exercise D 3,844
2025-09-10 GILD / Gilead Sciences, Inc. 4 O'Day Daniel Patrick M - Exercise D 10,427
2025-09-10 HALO / Halozyme Therapeutics, Inc. 4 LaBrosse Nicole M - Exercise D 12.07 11,271
2025-09-10 GILD / Gilead Sciences, Inc. 4 Wilfong Diane E. M - Exercise D 921
2025-09-10 RGEN / Repligen Corporation 4 Hunt Anthony M - Exercise D 33.87 20,000
2025-09-10 GILD / Gilead Sciences, Inc. 4 Telman Deborah H M - Exercise D 1,315
2025-09-10 ELUT / Elutia Inc. 4 Ferguson Matthew M - Exercise D 29,000
2025-09-10 ELUT / Elutia Inc. 4 Williams Michelle LeRoux M - Exercise D 12,500
2025-09-10 GILD / Gilead Sciences, Inc. 4 Dickinson Andrew D M - Exercise D 3,696
2025-09-10 GILD / Gilead Sciences, Inc. 4 Telman Deborah H F - Taxes D 115.25 -634
2025-09-10 GILD / Gilead Sciences, Inc. 4 Dickinson Andrew D F - Taxes D 115.25 -1,751
2025-09-10 ELUT / Elutia Inc. 4 Mills C Randal F - Taxes D 1.36 -9,664
2025-09-10 GILD / Gilead Sciences, Inc. 4 O'Day Daniel Patrick F - Taxes D 115.25 -4,949
2025-09-10 ELUT / Elutia Inc. 4 Williams Michelle LeRoux F - Taxes D 1.36 -3,950
2025-09-10 GILD / Gilead Sciences, Inc. 4 Mercier Johanna F - Taxes D 115.25 -1,819
2025-09-10 ELUT / Elutia Inc. 4 Ferguson Matthew F - Taxes D 1.36 -10,348
2025-09-10 GILD / Gilead Sciences, Inc. 4 Wilfong Diane E. F - Taxes D 115.25 -338
2025-09-09 VOR / Vor Biopharma Inc. 4 Reprogrammed Interchange LLC S - Sale D 2.0004 -449,226
2025-09-09 INKT / MiNK Therapeutics, Inc. 4 Buell Jennifer A - Award D 15.36 18,229
2025-09-08 TWST / Twist Bioscience Corporation 4 Cho Dennis S - Sale D 25.76 -269
2025-09-08 IPSC / Century Therapeutics, Inc. 4 Pfeiffenberger Brent S - Sale D 0.500 -488
2025-09-08 VOR / Vor Biopharma Inc. 4 Reprogrammed Interchange LLC S - Sale D 1.9897 -464,421
2025-09-08 TWST / Twist Bioscience Corporation 4 Leproust Emily M. S - Sale D 25.76 -2,265
2025-09-08 IPSC / Century Therapeutics, Inc. 4 Carr Douglas S - Sale D 0.500 -263
2025-09-08 TARS / Tarsus Pharmaceuticals, Inc. 4 LINK WILLIAM J PHD S - Sale D 57 -27,116
2025-09-08 IPSC / Century Therapeutics, Inc. 4 Russotti Gregory S - Sale D 0.500 -539
2025-09-08 TWST / Twist Bioscience Corporation 4 WERNER ROBERT F. S - Sale D 25.76 -235
2025-09-08 TWST / Twist Bioscience Corporation 4 Green Paula S - Sale D 25.76 -892
2025-09-08 PCVX / Vaxcyte, Inc. 4 Dhaliwal Harpreet S. F - Taxes D 32.41 -1,204
2025-09-08 PCVX / Vaxcyte, Inc. 4 PICKERING GRANT F - Taxes D 32.41 -7,356
2025-09-08 PCVX / Vaxcyte, Inc. 4 Wassil Jim F - Taxes D 32.41 -2,759
2025-09-08 PCVX / Vaxcyte, Inc. 4 GUGGENHIME ANDREW F - Taxes D 32.41 -2,890
2025-09-08 PCVX / Vaxcyte, Inc. 4 Cowan Elvia F - Taxes D 32.41 -482
2025-09-07 PCVX / Vaxcyte, Inc. 4 Cowan Elvia A - Award D 2,810
2025-09-05 VOR / Vor Biopharma Inc. 4 Reprogrammed Interchange LLC S - Sale D 1.9682 -400,000
2025-09-05 CGON / CG Oncology, Inc. 4 Mulay James S - Sale D 32.64 -7,465
2025-09-05 CGON / CG Oncology, Inc. 4 Mulay James S - Sale D 30.47 -12,342
2025-09-05 CGON / CG Oncology, Inc. 4 Mulay James S - Sale D 33.22 -3,113
2025-09-05 CGON / CG Oncology, Inc. 4 Mulay James S - Sale D 31.42 -4,095
P
Köp på öppna marknaden eller privat köp av icke-derivatsäkerhet
S
Köp på öppna marknaden eller privat försäljning av icke-derivatsäkerhet
A
Bevilja, tilldelning eller annat förvärv av värdepapper från företaget (såsom en option)
C
Omvandling av derivat
D
Försäljning eller överföring av värdepapper tillbaka til företaget
F
Betalning av lösenpris eller skatteskuld med del av värdepapper som erhållits från bolaget
G
Överlåtelse av värdepapper från eller till insidern
K
Aktieswappar och liknande säkringsaffärer
M
Utövande eller omvandling av derivatsäkerhet som erhållits från företaget (som en option)
V
En transaktion friviligt rapporterad på schema 4
J
Andra (med en fotnot som beskriver transaktionen)